AP-HP, Department of Otolaryngology, Hôpital Lariboisière, Université Paris Cité, Paris, France.
AP-HP, Department of Pediatric Endocrinology, Hôpital Bicêtre Paris Saclay, Le Kremlin- Bicêtre, France.
Orphanet J Rare Dis. 2024 Sep 12;19(1):339. doi: 10.1186/s13023-024-03299-3.
The main clinical features of pseudohypoparathyroidism (PHP)/inactivating parathyroid hormone/parathyroid hormone-related protein signaling disorders (iPPSD), including parathyroid hormone (PTH) resistance, brachydactyly and short stature, develop during middle and late childhood. Very few studies have addressed hearing loss in PHP/iPPSD patients, and these studies have yielded widely divergent conclusions. The aim of our study was to assess hearing and determine the predictive factors of hearing loss in patients with PHP/iPPSD.
Our retrospective cohort study was conducted between March 2019 and May 2020 in the Otolaryngology Department and the calcium phosphate reference center for rare diseases in Bicêtre Paris-Saclay Hospital, France. We retrospectively collected data from patients with PHP/iPPSDs (age, sex, genetic mutations, height, body mass index (BMI), PTH resistance, presence or absence of ectopic ossifications and brachydactyly). All patients underwent auditory investigations, including tonal and vocal audiometry. The primary outcome was the pure tone average (PTA). The PTA was compared with the norm according to the International Organization for Standardization. Hearing loss was defined as a PTA ≥ 20 db.
The median age of the patients was 15.6 years [9.5, 28.5]. Thirty-six patients were diagnosed with iPPSD2, and eight were diagnosed with iPPSD3. Twenty-six of them (59%) were female. Hearing impairment was confirmed in 17 patients (39%). The mean PTA and the mean SRT of the deaf ears were 40 ± 26 db and 31 ± 14 db. The mean difference in the PTA between the patients and the normal controls was 11.4 db (p = 0.00002). Short stature and the presence of ectopic ossifications were two significant predictive factors of hearing loss (p = 0.009 and p = 0.03, respectively). Sex, BMI, PTH resistance, mutation category and brachydactyly were not associated with an increased risk of hearing loss (p = 0.19, p = 0.41, p = 0.13, p = 0.50, p = 0.19, respectively).
Our study confirmed the frequency of hearing loss in patients with PHP/iPPSD disease (prevalence = 39%). A diagnosis of PHP/iPPSD should trigger auditory investigations and follow-up, especially when short stature and/or ectopic ossifications are present.
假性甲状旁腺功能减退症(PHP)/甲状旁腺激素失活/甲状旁腺激素相关蛋白信号障碍(iPPSD)的主要临床特征包括甲状旁腺激素(PTH)抵抗、短指(趾)畸形和身材矮小,这些特征在儿童中期和晚期发展。极少数研究探讨了 PHP/iPPSD 患者的听力损失,且这些研究得出了广泛不同的结论。本研究旨在评估听力,并确定 PHP/iPPSD 患者听力损失的预测因素。
本回顾性队列研究于 2019 年 3 月至 2020 年 5 月在法国比塞特尔巴黎萨克雷医院耳鼻喉科和钙磷罕见病参考中心进行。我们回顾性收集了 PHP/iPPSD 患者(年龄、性别、基因突变、身高、体重指数(BMI)、PTH 抵抗、是否存在异位骨化和短指(趾)畸形)的数据。所有患者均接受了听觉检查,包括纯音听阈测试和言语测听。主要结局为纯音平均听阈(PTA)。根据国际标准化组织的标准,将 PTA 与正常值进行比较。听力损失定义为 PTA≥20dB。
患者的中位年龄为 15.6 岁[9.5,28.5]。36 例患者被诊断为 iPPSD2,8 例被诊断为 iPPSD3。其中 26 例(59%)为女性。17 例(39%)患者确诊存在听力障碍。聋耳的平均 PTA 和平均言语识别阈分别为 40±26dB 和 31±14dB。患者与正常对照组的 PTA 平均差值为 11.4dB(p=0.00002)。身材矮小和异位骨化是听力损失的两个显著预测因素(p=0.009 和 p=0.03)。性别、BMI、PTH 抵抗、突变类别和短指(趾)畸形与听力损失风险增加无关(p=0.19、p=0.41、p=0.13、p=0.50、p=0.19)。
本研究证实了 PHP/iPPSD 患者听力损失的频率(患病率=39%)。诊断为 PHP/iPPSD 时应进行听觉检查和随访,尤其是当存在身材矮小和/或异位骨化时。